Organization Profile

You just read:

Opdivo™ (nivolumab) demonstrates superior survival compared to standard of care (docetaxel) for previously-treated squamous non-small cell lung cancer in phase 3 trial

News provided by

Bristol-Myers Squibb Canada

Jun 03, 2015, 05:59 ET